Common use of Pre-Existing Competitive Programs of an Acquirer Clause in Contracts

Pre-Existing Competitive Programs of an Acquirer. If, at any time during the Agreement Term, a Change of Control of a Party occurs involving a Person that, at the time of the completion of such Change of Control, is Developing or Commercializing a product that would violate the terms of Section 5.1.1 or Section 5.1.2, as applicable (such pre-existing competitive product, a “Pre-Existing Competing Product,”), then such Party shall not be deemed in breach of its obligations under Section 5.1.1 or Section 5.1.2, as applicable, with respect to such Pre-Existing Competing Product (and the restrictions set forth therein will not apply to such Pre-Existing Competing Products); provided that, following such Change of Control, such acquired Party will separate its Development and Commercialization activities under this Agreement from its development and commercialization activities relating to such Pre-Existing Competing Product (“Competing Activities”) and such Party will, and (if applicable) will cause the acquiring Affiliate to, (a) establish separate teams to conduct Development activities under this Agreement and development activities related to such Pre-Existing Competing Product, (b) prevent any Know-How that is Confidential Information relating to the Development or Commercialization of the applicable Product from being disclosed to, or used by, individuals performing such Competing Activities, and (c) not use or reference any Know-How that is Confidential Information or conduct any activities Covered by any Patents, in each case, Controlled by the Party involved in the Change of Control or the acquisition or its Affiliates prior to the effective date of the Change of Control or the acquisition, as applicable, in the development, manufacture, or commercialization of the Pre-Existing Competing Product.

Appears in 2 contracts

Samples: License Agreement (Ionis Pharmaceuticals Inc), License Agreement (Akcea Therapeutics, Inc.)

AutoNDA by SimpleDocs

Pre-Existing Competitive Programs of an Acquirer. If, at any time during the Agreement Term, a Change of Control of a Party occurs involving a Person that, at the time of the completion execution of such Change of Control, is Developing (A) developing or Commercializing commercializing a product that would violate (1) Competitive Product or (2) Competitive Indication Product within the terms of Section 5.1.1 or Section 5.1.2, as applicable Field (such pre-existing competitive productCompetitive Products and Competitive Indication Products, each, a “Pre-Existing Competitive Product”) or (B) is engaged in a Competitive Program or Competitive Indication Program (such pre-existing Competitive Programs and Competitive Indication Programs, each, a “Pre-Existing Competitive Program,” and such Person being hereinafter referred to as a “Competing Product,Collaboration Acquirer”), then in each case ((A) and (B)): (a) such Party shall not be deemed in breach promptly provide written notice to the other Party of its obligations under Section 5.1.1 or Section 5.1.2, as applicable, with respect to such Pre-Existing Competing Product (and the restrictions set forth therein will not apply to such Pre-Existing Competing Products); provided that, following such Change of Control; (b) if such Change of Control involved Ionis, then Biogen may elect that some or all of the Biogen Reduced Participation and Information Obligations will apply to the Collaboration Programs to which the Pre-Existing Competitive Product or Pre-Existing Competitive Program relate; (c) such acquired Party will shall conduct activities pursuant to Section 12.6 to separate its Development and Commercialization activities under this Agreement from its development and commercialization activities relating to any Pre-Existing Competitive Product(s) and Pre-Existing Competitive Program(s); and (d) the research, development, manufacture or commercialization of any Pre-Existing Competitive Product(s) by a Competing Collaboration Acquirer will not be a violation of such Party’s exclusivity covenants under Section 2.1.1 and Section 12.5.2(a) will not apply to any such Pre-Existing Competing Competitive Product (“Competing Activities”) and such Party will, and (if applicable) will cause the acquiring Affiliate to, (a) establish separate teams to conduct Development activities under this Agreement and development activities related to such or Pre-Existing Competing Product, (bCompetitive Program; provided that the conditions of Section 12.5.1(a) prevent any Know-How that is Confidential Information relating to the Development or Commercialization of the applicable Product from being disclosed to, or used by, individuals performing such Competing Activities, and (cSection 12.5.1(c) not use or reference any Know-How that is Confidential Information or conduct any activities Covered by any Patents, in each case, Controlled by the Party involved in the Change of Control or the acquisition or its Affiliates prior to the effective date of the Change of Control or the acquisition, as applicable, in the development, manufacture, or commercialization of the Pre-Existing Competing Productare satisfied.

Appears in 1 contract

Samples: Neurology Drug Discovery and Development Collaboration, Option and License Agreement (Ionis Pharmaceuticals Inc)

AutoNDA by SimpleDocs

Pre-Existing Competitive Programs of an Acquirer. If, at any time during the Agreement Term, a Change of Control of a Party occurs involving a Person that, at the time of the completion execution of such Change of Control, is Developing (A) developing or Commercializing commercializing a product that would violate Competitive Product or Competitive Indication Product within the terms of Section 5.1.1 or Section 5.1.2, as applicable Field (such pre-existing competitive productCompetitive Products and Competitive Indication Products, each, a “Pre-Existing Competitive Product”) or (B) is engaged in a Competitive Program or Competitive Indication Program (such pre-existing Competitive Programs and Competitive Indication Programs, each, a “Pre-Existing Competitive Program,” and such Person being hereinafter referred to as a “Competing Product,Collaboration Acquirer”), then in each case ((A) and (B)): (a) such Party shall not be deemed in breach promptly provide written notice to the other Party of its obligations under Section 5.1.1 or Section 5.1.2, as applicable, with respect to such Pre-Existing Competing Product (and the restrictions set forth therein will not apply to such Pre-Existing Competing Products); provided that, following such Change of Control; (b) if such Change of Control involved Ionis, then Biogen may elect that some or all of the Biogen Reduced Participation and Information Obligations will apply to the Collaboration Programs to which the Pre-Existing Competitive Product or Pre-Existing Competitive Program relate; (c) such acquired Party will shall conduct activities pursuant to Section 12.6 to separate its Development and Commercialization activities under this Agreement from its development and commercialization activities relating to any Pre-Existing Competitive Product(s) and Pre-Existing Competitive Program(s); and (d) the research, development, manufacture or commercialization of any Pre-Existing Competitive Product(s) by a Competing Collaboration Acquirer will not be a violation of such Party’s exclusivity covenants under Section 2.1.1 and Section 12.5.3(a) will not apply to any such Pre-Existing Competing Competitive Product (“Competing Activities”) and such Party will, and (if applicable) will cause the acquiring Affiliate to, (a) establish separate teams to conduct Development activities under this Agreement and development activities related to such or Pre-Existing Competing Product, (bCompetitive Program; provided that the conditions of Section 12.5.2(a) prevent any Know-How that is Confidential Information relating to the Development or Commercialization of the applicable Product from being disclosed to, or used by, individuals performing such Competing Activities, and (cSection 12.5.2(c) not use or reference any Know-How that is Confidential Information or conduct any activities Covered by any Patents, in each case, Controlled by the Party involved in the Change of Control or the acquisition or its Affiliates prior to the effective date of the Change of Control or the acquisition, as applicable, in the development, manufacture, or commercialization of the Pre-Existing Competing Productare satisfied.

Appears in 1 contract

Samples: New Strategic Neurology Drug Discovery and Development Collaboration, Option and License Agreement (Ionis Pharmaceuticals Inc)

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!